Omega-3 in the treatment of schizophrenia

The effect of omega-3 on negative and positive symptoms in patients with chronic schizophrenia: a double blind and placebo controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138811022935N3

Enrollment

Registered

2010-10-07

Start date

2010-08-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: Tablet chlorpromazine (1000mg/day ) or equivalent doses of typical antipsychotics combined with 3000mg/day of omega-3 as intervention group for 6 months. Intervention 2: Tablets chlorp

Treatment - Drugs

Placebo

Tablet chlorpromazine (1000mg/day ) or equivalent doses of typical antipsychotics combined with 3000mg/day of omega-3 as intervention group for 6 months

Tablets chlorpromazine(1000 mg/day) or equivalent doses of typical antipsychotics combined with placebo as control group for 6 months

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age between 18 and 60, diagnosis of Schizophrenia based on DSM IV, chronic Schizophrenia Exclusion Criteria: Substance dependence, any serious medical problem

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and 6 months after beginnig of treatmen. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzin Rezaei

Kurdistan University of Medical Sciences

farrezaei@muk.ac.ir; Farzin.Rezaie@uok.ac.ir ; frrezaie@yahoo.com+98 87 1666 0025

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026